Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2109 S Oak St #100a, Champaign, IL 61820, USA
- Website
- epivara.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Insigna, Inc. (doing business as Epivara, Inc.), a minority-owned, Asian-Pacific American–owned for-profit corporation headquartered in Champaign, Illinois, is a Small Business Innovation Research (SBIR) grant recipient under the National Institute of Food and Agriculture and National Science Foundation, developing pharmaceutical and biotech solutions for animal welfare and population management. The vendor operates exclusively as a prime recipient on federal research grants; no federal contracts or contract sub-awards appear in the source.
Insigna's grant portfolio centers on reproductive endocrinology and animal sterilization. The National Institute of Food and Agriculture awarded $650,000 on September 1, 2026, under SBIR (CFDA 10.212) to develop and evaluate INEUTER-S, a biodegradable, single-dose implant designed to prevent boar taint and testicular development in piglets without surgical castration, running through August 31, 2028. Work is performed in Champaign, Illinois, and includes dose characterization, pharmacokinetic studies, and efficacy evaluation at a university research farm and commercial swine operation. The National Science Foundation awarded a Phase I SBIR grant on November 1, 2024, completing March 31, 2027, for development of a non-surgical sterilization implant for female cats, addressing the market need of over 2 million female kittens born annually in the United States. A third grant from NIFA (July 1, 2022, through October 31, 2023) supported the earlier INEUTER program for surgical castration replacement in pigs.
Customer concentration is split between the Department of Agriculture's National Institute of Food and Agriculture (two awards) and the National Science Foundation, including its Division of Industrial Innovation (two awards combined). Total dollars obligated across all four awards stand at $1.4 million. Activity is sparse and episodic — one award per year in 2021 and 2022, then a gap until 2024, then the 2026 award — with two grants (the NSF cat-sterilization Phase I and the 2026 NIFA pig-implant award) facing ultimate completion inside the next twenty-four months and therefore eligible for Phase II or follow-on funding.
Quick answers
Is Insigna, Inc. registered in SAM.gov?
Yes. Insigna, Inc.'s SAM.gov registration is active through February 1, 2027.
What is Insigna, Inc.'s CAGE code?
Insigna, Inc.'s CAGE code is 8BNA4, and its Unique Entity ID (UEI) is JGXWKCJNGZ15.
What is Insigna, Inc.'s most recent federal award?
Insigna, Inc.'s most recent federal grant award is Most male piglets raised for pork in the united states are surgically castrated during their first week of life to… (20263941046787), from Institute of Food Production and Sustainability (NIFA), on September 1, 2026.
On GovTribe
See Insigna, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors